首页> 外文期刊>生物医学研究杂志(英文版) >Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients: A retrospective study of 525 patients
【24h】

Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients: A retrospective study of 525 patients

机译:新辅助化疗对525例乳腺癌患者激素受体和Ki67表达的影响

获取原文
获取原文并翻译 | 示例
       

摘要

This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese female breast cancer patients. The expression of estrogen receptor (ER), progesterone receptor (PR) and Ki67 among 525 neoadjuvant chemotherapy cases was studied by immunohistochemistry. Differences between specimens made through preoperative core needle biopsy and excised tissue biopsy were observed. The positive rates of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy were 65.3% and 63.2%, 51.0% and 42.6%, 65.6% and 43.4%, respectively. The expression of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy had no statistically significant difference. However, after neoadjuvant chemotherapy, the discordance rates of ER,PR and Ki67 were 15.2% (79/521), 26.9% (140/520) and 44.8% (225/502),respectively. The ER, PR and Ki67 status changed from positive to negative in 7.5% (39/521),13.3% (69/520) and 21.1% (106/502) of the patients, whereas ER, PR and Ki67 status changed from negative to positive in 7.7% (40/521),13.6% (71/520) and 23.7% (119/502) of the patients, respectively. These results showed that the status of some biomarkers changes after neoadjuvant chemotherapy and biomarker status needs to be reexamined to optimize adjuvant systemic therapy and better prognosis assessment.
机译:本研究旨在研究新辅助化疗对中国女性乳腺癌患者激素受体和Ki67表达的影响。通过免疫组织化学研究了525例新辅助化疗患者中雌激素受体(ER),孕激素受体(PR)和Ki67的表达。观察到通过术前核心针穿刺活检和切除的组织活检制成的标本之间的差异。 ER,PR和Ki67在芯针活检和切除的组织活检中的阳性率分别为65.3%和63.2%,51.0%和42.6%,65.6%和43.4%。 ER,PR和Ki67在核心针穿刺活检和切除组织活检中的表达无统计学差异。然而,新辅助化疗后,ER,PR和Ki67的不一致率分别为15.2%(79/521),26.9%(140/520)和44.8%(225/502)。 7.5%(39/521),13.3%(69/520)和21.1%(106/502)的患者的ER,PR和Ki67状态从阳性变为阴性,而ER,PR和Ki67状态从阴性变为阳性分别在7.7%(40/521),13.6%(71/520)和23.7%(119/502)的患者中呈阳性。这些结果表明,新辅助化疗后某些生物标志物的状态发生变化,需要重新检查生物标志物的状态以优化辅助性全身治疗和更好的预后评估。

著录项

  • 来源
    《生物医学研究杂志(英文版)》 |2018年第3期|191-197|共7页
  • 作者单位

    Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;

    Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;

    Department of Thyroid and Breast Surgery, Liuzhou People's Hospital Liuzhou, Guangxi 545006, China;

    Department of Oncology and Radiology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;

    Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;

    Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;

    Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;

    Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;

    Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;

  • 收录信息 中国科学引文数据库(CSCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 遗传学实验(实验遗传学)、实验方法及设备;
  • 关键词

  • 入库时间 2022-08-19 03:47:46
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号